Thomas Strungmann is a German pharmaceutical entrepreneur who has a net worth of $3.6 billion. Thomas Strungmann and his twin, Andreas, rose to riches together with the formation of generic drug maker Hexal AG, which transformed into the second-largest generic drug maker in the country.
An alumnus of Augsburg University in Business Administration, Thomas teamed up with his brother in 1986 to set up Hexal AG. They successfully run and developed the company until 2005, when they sold the business along with their 68% stake in Eon Lab (now based in the U.S.) to Novartis for $7.5 billion. Subsequently, the duo invested into several biotech companies based in Germany through their Athos Service GmbH and Santo Holding. Thomas Strungmann is also said to have an extensive collection of Swiss watches and modern art pieces in his possession. Away from business, he is a married man and a father of four.
|Net Worth:||$3.6 Billion|
|Date of Birth:||1950|